Biotech startup touts biomarker effect in PhI ALS study

A small Palo Alto, CA-based biotech has garnered some fresh attention for itself after touting the results of a small Phase I study designed to test its lead drug by measuring its impact on a key biomarker for Lou Gehrig's disease, or amyotrophic lateral sclerosis. While most developers focus their Phase I studies entirely on safety and tolerability, Neuraltus chose to also gauge the fluctuation of blood levels of the biomarker--which was not disclosed--24 hours after dosing. The developer, which the San Francisco Business Times notes is hoping to use the data to help woo new investors, recruited 32 patients for the study. Report

Suggested Articles

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.